Illumina outlines path to high single-digit revenue growth and 20% margins by 2027 amid NovaSeq X acceleration

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Illumina Options Trading: A Deep Dive into Market Sentiment

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

United States Tumor Profiling Research Report 2025-2033: $7.44 Billion Market Analysis by Technique, Technology, Application, States and Competitive Landscape

The United States Tumor Profiling Market is projected to surge from US$ 3.41 billion in 2024 to US$ 7.44 billion by 2033, ...
StockStory.org on MSN

Illumina (NASDAQ:ILMN) Beats Q3 Sales Expectations

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates. Is now ...